| . | Total (n = 96) . | Genetic variants detected (P/LP) (n = 23) . | Genetic variants detected (VUS/LB) (n = 39) . | No genetic variants identified (n = 34) . |
|---|---|---|---|---|
| Gender, male n (%) | 69 (71.9) | 18 (78.3) | 27 (69.2) | 24 (70.6) |
| Age in months, median (IQR) | 132 (63.25–208) | 201 (112–214) | 116 (51–192) | 127 (74–99) |
| Age of onset of NS, months median (IQR) | 57.5 (26.5–158) | 152 (63–194) | 78 (23–145) | 42 (22.5–101.5) |
| Hypertension n (%) | 61 (63.5) | 18 (78.3) | 21 (53.8) | 21 (61.8) |
| Early SRNS, n (%) | 69 (71.9) | 18 (78.3) | 29 (74.4) | 22 (64.7) |
| Late SRNS, n (%) | 27 (28.1) | 5 (21.7) | 10 (25.6) | 12 (35.3) |
| Parents consanguineous marriage | 10 (10.4) | 6 (26) | 4 (10.3) | 0 |
| Family history | 23 (24) | 15 (65.2) | 7 (17.9) | 1 (2.9) |
| Syndromic features | 18 (18.8) | 13 (56.5) | 4 (10.3) | 0 |
| Baseline eGFR, median (IQR) | 83 (57–102) | 54 (44–83) | 87 (70–106) | 84.5 (74–99) |
| Hb, g%, median (IQR) | 11.5 (10.1–13) | 10.7 (9.6–11.9) | 11.7 (10.7–13.4) | 11.3 (10.0–13.4) |
| Albumin, g% mean (SD) | 2.7 (0.95) | 3.1 (1.05) | 2.6 (0.9) | 2.2 (1.75–2.90) |
| Creatinine, mg%, median (IQR) | 0.7 (0.5–1.7) | 1.3 (0.7–3.0) | 0.6 (0.4–1.3) | 0.6 (0.5–1.5) |
| Triglycerides, mg% mean (SD) | 200 (130–325) | 147 (110–291) | 213 (147–324) | 227 (150–411) |
| Total cholesterol, mg% median (IQR) | 236 (155–385) | 164 (141–396) | 246 (158–391) | 309 (210–390) |
| Follow-up, months median (IQR) | 27 (17–60) | 27 (19–57) | 20 (12–26) | 44 (38.5–92.5) |
| ACEi/ARB use, n% | 56 (58.3) | 13 (56.5) | 22 (56.4) | 21 (61.8) |
| . | Total (n = 96) . | Genetic variants detected (P/LP) (n = 23) . | Genetic variants detected (VUS/LB) (n = 39) . | No genetic variants identified (n = 34) . |
|---|---|---|---|---|
| Gender, male n (%) | 69 (71.9) | 18 (78.3) | 27 (69.2) | 24 (70.6) |
| Age in months, median (IQR) | 132 (63.25–208) | 201 (112–214) | 116 (51–192) | 127 (74–99) |
| Age of onset of NS, months median (IQR) | 57.5 (26.5–158) | 152 (63–194) | 78 (23–145) | 42 (22.5–101.5) |
| Hypertension n (%) | 61 (63.5) | 18 (78.3) | 21 (53.8) | 21 (61.8) |
| Early SRNS, n (%) | 69 (71.9) | 18 (78.3) | 29 (74.4) | 22 (64.7) |
| Late SRNS, n (%) | 27 (28.1) | 5 (21.7) | 10 (25.6) | 12 (35.3) |
| Parents consanguineous marriage | 10 (10.4) | 6 (26) | 4 (10.3) | 0 |
| Family history | 23 (24) | 15 (65.2) | 7 (17.9) | 1 (2.9) |
| Syndromic features | 18 (18.8) | 13 (56.5) | 4 (10.3) | 0 |
| Baseline eGFR, median (IQR) | 83 (57–102) | 54 (44–83) | 87 (70–106) | 84.5 (74–99) |
| Hb, g%, median (IQR) | 11.5 (10.1–13) | 10.7 (9.6–11.9) | 11.7 (10.7–13.4) | 11.3 (10.0–13.4) |
| Albumin, g% mean (SD) | 2.7 (0.95) | 3.1 (1.05) | 2.6 (0.9) | 2.2 (1.75–2.90) |
| Creatinine, mg%, median (IQR) | 0.7 (0.5–1.7) | 1.3 (0.7–3.0) | 0.6 (0.4–1.3) | 0.6 (0.5–1.5) |
| Triglycerides, mg% mean (SD) | 200 (130–325) | 147 (110–291) | 213 (147–324) | 227 (150–411) |
| Total cholesterol, mg% median (IQR) | 236 (155–385) | 164 (141–396) | 246 (158–391) | 309 (210–390) |
| Follow-up, months median (IQR) | 27 (17–60) | 27 (19–57) | 20 (12–26) | 44 (38.5–92.5) |
| ACEi/ARB use, n% | 56 (58.3) | 13 (56.5) | 22 (56.4) | 21 (61.8) |
eGFR, estimated glomerular filtration rate; Hb, haemoglobin; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
| . | Total (n = 96) . | Genetic variants detected (P/LP) (n = 23) . | Genetic variants detected (VUS/LB) (n = 39) . | No genetic variants identified (n = 34) . |
|---|---|---|---|---|
| Gender, male n (%) | 69 (71.9) | 18 (78.3) | 27 (69.2) | 24 (70.6) |
| Age in months, median (IQR) | 132 (63.25–208) | 201 (112–214) | 116 (51–192) | 127 (74–99) |
| Age of onset of NS, months median (IQR) | 57.5 (26.5–158) | 152 (63–194) | 78 (23–145) | 42 (22.5–101.5) |
| Hypertension n (%) | 61 (63.5) | 18 (78.3) | 21 (53.8) | 21 (61.8) |
| Early SRNS, n (%) | 69 (71.9) | 18 (78.3) | 29 (74.4) | 22 (64.7) |
| Late SRNS, n (%) | 27 (28.1) | 5 (21.7) | 10 (25.6) | 12 (35.3) |
| Parents consanguineous marriage | 10 (10.4) | 6 (26) | 4 (10.3) | 0 |
| Family history | 23 (24) | 15 (65.2) | 7 (17.9) | 1 (2.9) |
| Syndromic features | 18 (18.8) | 13 (56.5) | 4 (10.3) | 0 |
| Baseline eGFR, median (IQR) | 83 (57–102) | 54 (44–83) | 87 (70–106) | 84.5 (74–99) |
| Hb, g%, median (IQR) | 11.5 (10.1–13) | 10.7 (9.6–11.9) | 11.7 (10.7–13.4) | 11.3 (10.0–13.4) |
| Albumin, g% mean (SD) | 2.7 (0.95) | 3.1 (1.05) | 2.6 (0.9) | 2.2 (1.75–2.90) |
| Creatinine, mg%, median (IQR) | 0.7 (0.5–1.7) | 1.3 (0.7–3.0) | 0.6 (0.4–1.3) | 0.6 (0.5–1.5) |
| Triglycerides, mg% mean (SD) | 200 (130–325) | 147 (110–291) | 213 (147–324) | 227 (150–411) |
| Total cholesterol, mg% median (IQR) | 236 (155–385) | 164 (141–396) | 246 (158–391) | 309 (210–390) |
| Follow-up, months median (IQR) | 27 (17–60) | 27 (19–57) | 20 (12–26) | 44 (38.5–92.5) |
| ACEi/ARB use, n% | 56 (58.3) | 13 (56.5) | 22 (56.4) | 21 (61.8) |
| . | Total (n = 96) . | Genetic variants detected (P/LP) (n = 23) . | Genetic variants detected (VUS/LB) (n = 39) . | No genetic variants identified (n = 34) . |
|---|---|---|---|---|
| Gender, male n (%) | 69 (71.9) | 18 (78.3) | 27 (69.2) | 24 (70.6) |
| Age in months, median (IQR) | 132 (63.25–208) | 201 (112–214) | 116 (51–192) | 127 (74–99) |
| Age of onset of NS, months median (IQR) | 57.5 (26.5–158) | 152 (63–194) | 78 (23–145) | 42 (22.5–101.5) |
| Hypertension n (%) | 61 (63.5) | 18 (78.3) | 21 (53.8) | 21 (61.8) |
| Early SRNS, n (%) | 69 (71.9) | 18 (78.3) | 29 (74.4) | 22 (64.7) |
| Late SRNS, n (%) | 27 (28.1) | 5 (21.7) | 10 (25.6) | 12 (35.3) |
| Parents consanguineous marriage | 10 (10.4) | 6 (26) | 4 (10.3) | 0 |
| Family history | 23 (24) | 15 (65.2) | 7 (17.9) | 1 (2.9) |
| Syndromic features | 18 (18.8) | 13 (56.5) | 4 (10.3) | 0 |
| Baseline eGFR, median (IQR) | 83 (57–102) | 54 (44–83) | 87 (70–106) | 84.5 (74–99) |
| Hb, g%, median (IQR) | 11.5 (10.1–13) | 10.7 (9.6–11.9) | 11.7 (10.7–13.4) | 11.3 (10.0–13.4) |
| Albumin, g% mean (SD) | 2.7 (0.95) | 3.1 (1.05) | 2.6 (0.9) | 2.2 (1.75–2.90) |
| Creatinine, mg%, median (IQR) | 0.7 (0.5–1.7) | 1.3 (0.7–3.0) | 0.6 (0.4–1.3) | 0.6 (0.5–1.5) |
| Triglycerides, mg% mean (SD) | 200 (130–325) | 147 (110–291) | 213 (147–324) | 227 (150–411) |
| Total cholesterol, mg% median (IQR) | 236 (155–385) | 164 (141–396) | 246 (158–391) | 309 (210–390) |
| Follow-up, months median (IQR) | 27 (17–60) | 27 (19–57) | 20 (12–26) | 44 (38.5–92.5) |
| ACEi/ARB use, n% | 56 (58.3) | 13 (56.5) | 22 (56.4) | 21 (61.8) |
eGFR, estimated glomerular filtration rate; Hb, haemoglobin; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
